比较用于判定活体肝移植供肝脂肪变性的CT方法
本研究以肝穿刺活检为参考标准,回顾性纳入55例同时接受平扫CT与三期增强CT的潜在供肝者,比较肝脏衰减指数诊断肝脂肪变性的效能。肝静脉期增强CT中经脾脏校正的肝脏衰减测量与脂肪变性相关性最强,ROC曲线下面积大于0.9,可能有助于评估中重度脂肪变性供肝者并避免不必要的肝活检。
要点
- 肝静脉期增强CT中经脾脏校正的肝脏衰减测量与脂肪变性相关性最强(R 0.821;R2 0.674)。
- 肝静脉期增强CT经脾脏校正的肝脏衰减测量对脂肪变性定性诊断的AUC值大于0.9。
- 该作者认为该指标可能有助于评估中重度脂肪变性供肝者,从而避免不必要的肝活检。
核心结论
- 肝静脉期增强CT中经脾脏校正的肝脏衰减测量可能有助于评估中重度脂肪变性、不适合作为供肝的候选者,并可能使这些供肝候选者避免不必要的肝活检。
研究设计与样本
- 回顾性研究,经本院机构审查委员会批准,纳入55例同时接受平扫CT、三期增强CT及肝脏核心穿刺活检的潜在供肝者。
- 以肝穿刺活检为参考标准,分析平扫与增强CT上肝脏、脾脏及腰大肌多区域平均衰减测量值,并比较经脾脏和腰大肌校正与未校正的肝脏衰减测量。
- 采用线性回归和受试者工作特征(ROC)曲线分析评估CT指标与组织学脂肪变性之间的统计学关联。
诊断标准与关键数值
- 肝静脉期增强CT中经脾脏校正的肝脏衰减测量与脂肪变性相关性最强(R 0.821;R2 0.674 与 R 0.816;R2 0.665)。
- 肝静脉期增强CT中经脾脏校正的肝脏衰减测量对脂肪变性定性鉴别显示高诊断效能(AUC值大于0.9)。
临床应用与阅片要点
- 作者认为,肝静脉期增强CT中经脾脏校正的肝脏衰减测量可能有助于评估中重度脂肪变性供肝候选者,并可能避免这些候选者不必要的肝活检。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate and compare the diagnostic performance of non-enhanced computed tomography (NECT) and contrast-enhanced CT (CECT) attenuation indices in the assessment of hepatic steatosis by using biopsy as the reference standard.
MATERIALS AND METHODS: This retrospective study was approved by our Institutional Review Board. 55 Potential donors who underwent both NECT and triphasic CECT and core liver biopsy, were included the study. Average attenuation measurements that were obtained from multiple regions in liver, spleen, and psoas muscle on both unenhanced and CECT were used for analysis. Hepatic attenuation measurements were analyzed with and without normalization with the spleen and psoas muscle. Linear regression and receiver operating characteristic (ROC) curve analysis were used to evaluate the statistical association between CT indices and steatosis at histology.
RESULTS: Linear regression analysis confirmed the strongest correlation between steatosis and normalized measurements of hepatic attenuation with splenic attenuations on hepatic venous phase of CECT scan (R 0.821; R2 0.674 and R 0.816; R2 0.665, respectively). The use of ROC curve analysis also demonstrated that normalized measurements of hepatic attenuation with splenic attenuations on hepatic venous phase of CECT showed high diagnostic performance regarding the qualitative distinction of steatosis (AUC values greater than 0.9).
CONCLUSION: Attenuation measurements of liver normalized with spleen on hepatic venous phase may be useful in evaluating steatosis in donor candidates with moderate to severe steatosis who are unacceptable for liver donation. In this manner unnecessary liver biopsy may be avoided in those donor candidates.
引用
- Şeker M, Erol C, Sevmiş Ş, et al. Comparison of CT methods for determining graft steatosis in living donor liver transplantation. Abdom Radiol (NY). 2019. PMID: 30937504. doi:10.1007/s00261-019-01993-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。